image_printPrint Page


Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals

So much can happen in a few years with diabetes technology advancements. While we still don’t have a cure, it’s better to be diagnosed with type 1 diabetes now than it was a few years ago.

We now have options to delay the diagnosis and save some beta cells long after diagnosis.

A recent study analyzed the effects of a single 14-day course of teplizumab treatment on metabolic function and immune cells among participants at high risk for type 1 diabetes (T1D). In an extended follow-up of a previous report of teplizumab treatment, researchers found that the median time to diagnosis was 27.1 for patients that received the placebo and 59.6 months for teplizumab. 50% of teplizumab-treated were not diagnosed with T1D, compared to 22% of the placebo-treated group. Additionally, teplizumab treatment improved beta-cell function and reversed a decline in insulin secretion before enrollment, followed by stabilization of the declining C-peptide AUC seen with placebo treatment. In summary, a single course of teplizumab had lasting effects on delay of T1D diagnosis and improved beta-cell function in high-risk individuals. Overall, this trial showed improvement in metabolic responses and delay of diabetes with the use of teplizumab immunotherapy.

Original article: sciencemag.org

image_printPrint Page